BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37536738)

  • 1.
    de Jong AC; Segbers M; Ling SW; Graven LH; Mehra N; Hamberg P; Brabander T; de Wit R; van der Veldt AAM
    J Nucl Med; 2023 Oct; 64(10):1556-1562. PubMed ID: 37536738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of
    Bosch D; van der Velden KJM; Oving IM; Wyndaele DNJ; Weijs LE; van Schelven WD; Oyen WJG; Te Beek ET; van de Luijtgaarden ACM; Somford DM; Nagarajah J; Hermsen R; Mehra N; Gerritsen WR; van der Doelen MJ; van Oort IM
    J Nucl Med; 2024 Apr; 65(4):541-547. PubMed ID: 38423781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of [
    Pan J; Zhao J; Ni X; Zhu B; Hu X; Wang Q; Wei Y; Zhang T; Gan H; Wang B; Wu J; Song S; Liu C; Ye D; Zhu Y
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1822-1832. PubMed ID: 36719427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
    Shagera QA; Karfis I; Kristanto P; Spyridon S; Diamand R; Santapau A; Peltier A; Roumeguère T; Flamen P; Artigas C
    J Nucl Med; 2023 Dec; 64(12):1869-1875. PubMed ID: 37770114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic accuracy of
    Daniels H; Gilbert R; Bonin L
    J Med Imaging Radiat Sci; 2023 Sep; 54(3):545-555. PubMed ID: 37211439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [
    Kluge K; Einspieler H; Haberl D; Spielvogel C; Stoiber S; Vraka C; Papp L; Wunsch S; Egger G; Kramer G; Grubmüller B; Shariat S; Hacker M; Kenner L; Haug A
    J Nucl Med; 2024 Jan; 65(1):63-70. PubMed ID: 38050125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Experience with [
    Alan-Selcuk N; Beydagi G; Demirci E; Ocak M; Celik S; Oven BB; Toklu T; Karaaslan I; Akcay K; Sonmez O; Kabasakal L
    J Nucl Med; 2023 Oct; 64(10):1574-1580. PubMed ID: 37620050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with
    Telli T; Tuncel M; Karabulut E; Aksoy S; Erman M; Akdogan B; Caglar M
    Prostate; 2023 Jun; 83(8):792-800. PubMed ID: 36919876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
    Karimzadeh A; Heck M; Tauber R; Solaris E; Nekolla S; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I
    J Nucl Med; 2023 Aug; 64(8):1252-1258. PubMed ID: 37290796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC.
    Laarhuis BI; Janssen MJR; Simons M; van Kalmthout LWM; van der Doelen MJ; Peters SMB; Westdorp H; van Oort IM; Litjens G; Gotthardt M; Nagarajah J; Mehra N; Privé BM
    Clin Genitourin Cancer; 2023 Oct; 21(5):e352-e361. PubMed ID: 37164814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of thresholding methods for the quantification of [
    Kim M; Seifert R; Fragemann J; Kersting D; Murray J; Jonske F; Pomykala KL; Egger J; Fendler WP; Herrmann K; Kleesiek J
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2196-2209. PubMed ID: 36859618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using
    Denis CS; Cousin F; Laere B; Hustinx R; Sautois BR; Withofs N
    J Nucl Med; 2022 Dec; 63(12):1815-1821. PubMed ID: 35450960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
    Calderoni L; Maietti E; Farolfi A; Mei R; Louie KS; Groaning M; Fanti S
    J Nucl Med; 2023 Jun; 64(6):910-917. PubMed ID: 36635087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging of new target CDK19 in prostate cancer.
    Dai D; Yu J; Huang T; Li Y; Wang Z; Yang S; Li S; Li Y; Gou W; Li D; Hou W; Fan S; Li Y; Zhao Y
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3452-3464. PubMed ID: 37278941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Association Between [
    Chen M; Fu Y; Peng S; Zang S; Ai S; Zhuang J; Wang F; Qiu X; Guo H
    J Nucl Med; 2023 Oct; 64(10):1550-1555. PubMed ID: 37474268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective comparative study of [
    Gao X; Tang Y; Chen M; Li J; Yin H; Gan Y; Zu X; Cai Y; Hu S
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2177-2187. PubMed ID: 36811661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary results on response assessment using
    Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T
    Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated segmentation of lesions and organs at risk on [
    Yazdani E; Karamzadeh-Ziarati N; Cheshmi SS; Sadeghi M; Geramifar P; Vosoughi H; Jahromi MK; Kheradpisheh SR
    Cancer Imaging; 2024 Feb; 24(1):30. PubMed ID: 38424612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer.
    de Jong AC; Isebia KT; Ling SW; de Weerd V; Van NM; Kraan J; Martens JWM; Mehra N; Hamberg P; Lolkema MP; de Wit R; van der Veldt AAM; Wilting SM
    JCO Precis Oncol; 2023 Sep; 7():e2300156. PubMed ID: 38061007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.